[15] In August 2024, the SURMOUNT-1 three-year study (176-week treatment period) found that tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Amazon.com: The GLP-1 Advantage Beyond the Injections: Everything You Need to Know for Your GLP-1 Journey (Audible Audio Edition): Brittany Alana, Jacqueline Centofanti, Brittany Alana: Books
Yes, when taken at recommended doses
Ch sau 7 ngy, bn s hi lng vi ln da sng, mn mng m Angels Liquid 7 Day Glutathione 700 V-Cream mang li